According to Fortune Business Insights, the global nasal drug delivery market size stood at USD 42.39 billion in 2018 and is projected to reach USD 120.83 billion by 2032, exhibiting a CAGR of 7.9% during the forecast period. Europe dominated the global market with a share of 49.82% in 2018. Nasal drug delivery has become a widely researched area as companies continue developing small, portable, and user-friendly devices using advanced technologies. The nasal route is considered appropriate for drug delivery because it can provide a faster onset of action for the treatment of related diseases.

The market is witnessing technological developments focused on improving drug administration, patient convenience, and treatment adherence. Companies are exploring new biotherapeutics, including polypeptides, peptides, and antisense DNA, which are otherwise administered through injections. The development of innovative delivery systems and increasing interest in advanced inhalation technologies are expected to support market growth over the forecast period.

Market Overview

The nasal drug delivery market includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and nebulizers. These technologies are used across applications such as asthma and chronic obstructive pulmonary disease (COPD), while distribution takes place through hospital pharmacies, retail pharmacies, and online pharmacies. The market report provides qualitative and quantitative insights into market size, growth rates, market dynamics, emerging trends, technological advancements, product launches, and competitive developments.

Based on type, dry powder inhalers hold a leading position. Their advantages include product stability, the ability to deliver low or high doses according to requirements, and lower susceptibility to microorganisms. Metered dose inhalers hold the second position, although their use can be challenging because correct administration requires multiple steps. Nebulizers represent a comparatively smaller share because of their major use among hospitalized patients rather than home healthcare settings.

𝗧𝗼𝗽 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗜𝗻 𝗧𝗵𝗲 Market

• Consort Medical plc.
• AptarGroup, Inc.
• Vectura Group plc
• 3M
• H&T Presspart Manufacturing Ltd.
• Nemera
• GOFIRE INC.
• Teva Pharmaceutical Industries Ltd.
• Others

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀 & 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀:

The increasing prevalence of asthma and COPD is a major factor supporting market growth. Fortune Business Insights notes that around 300 million people globally suffer from asthma, increasing the patient population requiring effective medication delivery. The rising number of hospital admissions associated with COPD is also contributing to demand for inhalers, particularly DPIs and MDIs.

Another growth factor is the introduction of off-patent drugs for respiratory care. Patent expirations of branded inhaled medications and pressure on healthcare budgets are encouraging the development of generic inhaled medicines. Lower treatment costs can increase awareness and adoption of DPIs and MDIs. Patient awareness regarding the benefits of inhalation devices is also expected to support demand.

However, limited patient awareness regarding correct dose administration remains a restraint. Improper use of drug delivery equipment, insufficient training, and difficulties experienced by older adults can result in incorrect usage and under-dosing. These challenges may reduce the adoption of drug delivery devices and negatively affect market growth.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗧𝗿𝗲𝗻𝗱𝘀

The rising adoption of smart inhalers represents an important market trend. Connected devices are increasingly being developed to help patients monitor inhaler use, improve dose accuracy, and receive medication reminders. Fortune Business Insights highlights the development of connected smart devices using Bluetooth technology to detect inhaler use and support medication adherence. Such technologies can provide patients with precise information while making inhaler operation easier.

Awareness campaigns are another factor influencing adoption. Government bodies and companies have conducted initiatives to communicate the importance and benefits of inhalers for asthma and COPD patients. These initiatives are intended to improve awareness about asthma control and encourage greater use of inhalation therapies.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:

The competitive landscape includes established companies focusing on innovative drug delivery solutions and advanced inhalation technologies. AptarGroup, Inc. provides drug delivery solutions for pharmaceutical, healthcare, and biotechnology applications. The company has focused on innovation in drug delivery and has supported regulatory submissions involving nasal drug delivery technologies. 

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀:

By type, the market is segmented

By Type (Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), and Nebulizers)

By Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/nasal-drug-delivery-market-100415 

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀:

Europe held the largest market share, accounting for 49.82% in 2018, and is expected to retain its leading position. The region benefits from a high prevalence of COPD and asthma, widespread awareness of inhaler benefits, and increasing acceptance of smart inhalers. Europe is anticipated to grow at a CAGR of 6.8% during the forecast period.

Asia-Pacific is expected to witness healthy growth due to increasing inhaler adoption, government awareness initiatives, and expanding investments by biopharmaceutical companies in novel DPI and MDI technologies. Japan's market is expected to reach USD 1.37 billion by 2025, while China is projected to record a strong CAGR of 10.60% during the forecast period.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗰𝗼𝗽𝗲:

The future outlook for the nasal drug delivery market is supported by continued technological advancements, increasing adoption of user-friendly inhalers, development of smart connected devices, and growing demand for effective respiratory disease management. The increasing prevalence of asthma and COPD, patient awareness initiatives, generic respiratory medications, and investments in innovative drug delivery technologies are expected to create opportunities for market expansion. The continued development of advanced devices for accurate, convenient, and patient-friendly drug administration is likely to remain an important area of focus.

What’s Driving Japan’s Market? Discover the Latest -Nasal Drug Delivery Market- Insights